# 2026-20443: Cancer Risk DNA Sequencers Get FDA Fast-Track Classification

2026-20443, Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2026-10-06, effective 2026-10-06; PRIA reads it as touching household money (as of 2026-10-13).

- Canonical: https://policyrisk.com/federal-register/2026-20443
- As of: 2026-10-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-20443
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the High Throughput DNA Sequencing for Hereditary Cancer Predisposition Assessment Test System
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 63487
- Published: 2026-10-06
- Effective: 2026-10-06
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-13

## In one line

Cancer Risk DNA Sequencers Get FDA Fast-Track Classification

## Summary

The FDA is officially putting high throughput DNA tests for hereditary cancer risk into a safer, easier-to-access category called Class II. This change means these tests will have special rules to keep them safe and effective, while also making it simpler for patients to get these life-saving tools. The new classification took effect on October 6, 2026, helping speed up innovation without extra costs for companies or patients.

## Abstract

The Food and Drug Administration (FDA) is classifying the high throughput DNA sequencing for hereditary cancer predisposition assessment test system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the high throughput DNA sequencing for hereditary cancer predisposition assessment test system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Class II Reclassification Expands Access: benefit, high. The FDA has classified high throughput DNA sequencing tests for hereditary cancer predisposition as Class II (special controls). This classification is effective October 6, 2026 (and was applicable September 29, 2023) and the FDA says it will provide reasonable assurance of safety and effectiveness…
- Prescription Requirement and Use Limits: cost, low. These hereditary cancer sequencing tests are for prescription use only and are not intended for screening, prenatal testing, or as a stand-alone diagnostic test. The rule explicitly limits use to aiding hereditary cancer predisposition assessment by qualified health care professionals.
- Required Accuracy and Validation Standards: benefit, high. Manufacturers must meet detailed validation and performance requirements, including minimum specimen testing counts and accuracy thresholds: for BRCA1 and BRCA2 at least 120 variant-positive specimens; at least 40 variant-positive specimens for other high-clinical-significance genes; overall accura…
- Mandatory Patient and Provider Labeling Details: benefit, medium. Labeling must include intended specimen types and validated mutation types, the testing facility name, a plain summary of how the test works and how to interpret results, performance summaries, and many limiting statements (for example: that the test is not for stand-alone diagnosis or prenatal tes…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-20443 on federalregister.gov](https://www.federalregister.gov/documents/2026/10/06/2026-20443/medical-devices-immunology-and-microbiology-devices-classification-of-the-high-throughput-dna)
- [2026-20443 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-10-06/pdf/2026-20443.pdf)

## Related
- [Previous: 2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monito…](https://policyrisk.com/federal-register/2026-20441)
- [Next: 2026-20447, Transparency in Coverage](https://policyrisk.com/federal-register/2026-20447)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-20443 (as of 2026-10-13).
